DSpace Repository

Cardiac Manifestations in Patients with COVID-19: A Scoping Review.

Show simple item record

dc.contributor.author Peiris, Sasha
dc.contributor.author Ordunez, Pedro
dc.contributor.author DiPette, Donald
dc.contributor.author Padwal, Raj
dc.contributor.author Ambrosi, Pierre
dc.contributor.author Toledo, Joao
dc.contributor.author Stanford, Victoria
dc.contributor.author Lisboa, Thiago
dc.contributor.author Aldighieri, Sylvain
dc.contributor.author Reveiz, Ludovic
dc.date.accessioned 2023-11-20T17:32:57Z
dc.date.available 2023-11-20T17:32:57Z
dc.date.issued 2022
dc.identifier.citation LISBOA, T. C. et al. Cardiac Manifestations in Patients with COVID-19: A Scoping Review. Global Heart, v. 17, p. 2, 2022. Disponível em: https://globalheartjournal.com/articles/10.5334/gh.103. Acesso em: 17 nov. 2023 pt_BR
dc.identifier.uri http://hdl.handle.net/11690/3743
dc.description.abstract Background: Coronavirus disease 2019 (COVID-19), commonly affects the lungs, but the involvement of other organs, particularly the heart, is highly prevalent as has been reported in several studies. The overall aim of this review was to provide an in-depth description of the available literature related to the cardiac system and COVID-19 infection. It focuses on type and the frequency of cardiac manifestations, clinical parameters and cardiac biomarkers that support the prognosis of COVID-19 patients, and the cardiac adverse events and outcomes related to pharmacotherapy. Methods: A scoping review was conducted searching Embase, PubMed, Epistomonikos, Medrxiv, BioRxiv databases, up to November 2020, for systematic reviews relevant to cardiac manifestations in adult COVID-19 patients. Relevant articles were screened and extracted to summarize key outcomes and findings. Results: A total of 63 systematic reviews met the inclusion criteria. The overall frequency of acute cardiac injury ranged from 15% to 33% in the reporting studies. The main cardiac complications were arrhythmias (3.1% to 6.9% in non-severe patients, 33.0% to 48.0% in severe disease), acute coronary syndromes (6% to 33% in severe disease), and myocarditis. Most studies found no association with the use of Reninangiotensin-aldosterone system inhibitors (RAASI) with COVID-19 outcomes such as susceptibility to infection, hospitalization, severity, and mortality. Conclusion: This study provided an overview of the several cardiac complications associated with Covid-19. Cardiac injury, arrhythmias, myocarditis, cardiac failure, and acute coronary syndrome, are prevalent and clinically significant and associated with COVID-19 disease severity and mortality. Other studies are needed to clearly identify what is the part of viral heart infection and what is the part of cardiac injury secondary to acute respiratory failure and inflammation. In the therapeutic field, these systematic reviews gave heterogenous results. This underlines the importance of randomized trials to determine the right therapeutic approach. pt_BR
dc.language.iso en_US pt_BR
dc.publisher Global Heart pt_BR
dc.rights Open Access en_US
dc.subject COVID-19 pt_BR
dc.subject Heart pt_BR
dc.subject Complications pt_BR
dc.subject Heart Diseases pt_BR
dc.subject Review pt_BR
dc.title Cardiac Manifestations in Patients with COVID-19: A Scoping Review. pt_BR
dc.type Artigo de periódico pt_BR


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account